When should Wegovy start working — and what to expect at each stage

Step 1, weeks 1 to 4: the starter dose sets the stage

The treatment begins at 0.25 mg once weekly. This is not a therapeutic dose in the sense of delivering maximum appetite suppression; its job is to let your gut and brain adjust to semaglutide before the dose climbs. Most people notice something (a little less interest in finishing a plate, a shorter hunger window between meals) but it is subtle. Some notice almost nothing at all during this period, and that is completely normal.

Side effects are also most common here. Nausea, queasiness after eating, and occasional loose stools are the body responding to a new mechanism: semaglutide slows gastric emptying and acts on appetite-regulating receptors in the brain. The NHS medicines page for semaglutide describes these GI effects as typically mild-to-moderate and settling within days to a couple of weeks. Eating smaller portions, avoiding very fatty meals, and staying well-hydrated all help.

Weight change in week one to four is usually modest. A kilo or two is plausible for some people; nothing visible on the scales is equally common. If you are wondering when Wegovy starts working and what early signs to look out for, neither outcome at this stage tells you much about what the next three months will bring.

Step 2, months 2 to 4: dose increases and appetite shifts

At the four-week mark, dose increases begin (0.5 mg, then 1.0 mg, then 1.7 mg, each roughly a month apart). This is where most people start to feel Wegovy working in a way they can put into words: meals feel filling sooner, snacking between meals drops off, and the internal noise around food quietens. For many, this is the most striking phase.

Weight loss tends to accelerate after each dose step. A steady loss of around half a kilogram to one kilogram per week is broadly consistent with what clinical evidence suggests at this stage, though individual responses vary considerably, genetics, starting weight, diet quality, and activity levels all play a part. If you are curious about how the results evidence breaks down, our semaglutide overview walks through the STEP trial data in more detail.

It is worth knowing that some people reach their optimal appetite suppression at 1.0 mg or 1.7 mg rather than the maximum dose, and prescribers take that into account when reviewing progress. The titration ladder is a guide, not a contract.

Step 3, months 4 to 6 and beyond: maintenance dose and steady accumulation

Reaching the 2.4 mg maintenance dose (or the highest tolerated dose) is when cumulative weight loss really starts to add up. The STEP 1 trial, published in the New England Journal of Medicine, followed adults over 68 weeks and found an average reduction of around 15% of body weight at 2.4 mg. That figure covers the full treatment period, it is the payoff for months of steady dose building, not something that arrives at week four.

By month five or six, most people on an effective dose will have seen consistent downward movement on the scales. If you are wondering when you should start losing weight on Wegovy and whether your progress is on track, or whether a dose increase makes sense, a clinical review is the right moment to raise it. Our prescribers look at this at every repeat, there are no automatic renewals at nume, and each order is assessed individually.

One practical note: if you order before midday on a weekday, a clinically approved prescription is dispatched the same day and arrives the next working day, so there is no gap in treatment during a busy week. Questions about your personal timeline are best directed to your prescriber or our support team, who are available seven days a week.

For those weighing up the overall cost of Wegovy treatment alongside realistic expectations, understanding the timeline matters, a six-month commitment looks different once you know where in that arc the results typically land. And if you are at the beginning and unsure about the right time to start, that decision belongs with a prescriber who can review your full picture.

The NICE appraisal of semaglutide (TA875) does note that if weight loss is under 5% after six months at the maintenance dose, continuing should be reviewed. That threshold is a clinical benchmark, not a reason for early alarm, but it is worth knowing before you start.

Speak to our prescribers if you would like a clinical view on whether Wegovy is working as expected at your current dose, or to begin an assessment. Start your free consultation here.